What is the diagnostic approach for systemic lupus erythematosus?

Diagnosis of Systemic Lupus Erythematosus

The diagnosis of SLE requires positive ANA testing (at 1:160 dilution or higher) followed by confirmatory autoantibody testing, integrated with clinical manifestations across multiple organ systems using the EULAR/ACR 2019 classification criteria as a diagnostic framework.

Diagnostic Algorithm

Step 1: Initial Screening with ANA Testing

• Order ANA by indirect immunofluorescence assay (IIFA) on HEp-2 cells as the gold standard screening test 1
• Use 1:160 dilution as the cut-off in unselected populations 2
• A negative ANA at 1:160 makes SLE highly unlikely, though not impossible 1, 2

Critical caveat: In high clinical suspicion cases with negative ANA, proceed directly to specific antibody testing (anti-Ro/SSA, anti-ribosomal P, anti-Jo-1) as these can be present despite negative ANA 1, 2

Step 2: Confirmatory Autoantibody Testing (When ANA Positive)

Use a dual-screening strategy for anti-dsDNA antibodies 2:

1. First: Solid phase assay (FEIA, ELISA, or CLIA) - high sensitivity
2. Second: Crithidia luciliae immunofluorescence test (CLIFT) - high specificity, pathognomonic when positive

Interpretation of anti-dsDNA results 2:

• SPA positive + CLIFT positive: SLE very likely
• SPA positive + CLIFT negative: Evaluate in clinical context; not diagnostic alone
• SPA negative + CLIFT positive: SLE likely (rare but significant)
• Both negative: Does not exclude SLE; proceed to anti-ENA testing

Step 3: Anti-ENA Panel Testing

Order when ANA is positive 2:

• Anti-Sm (Smith antibodies): Highly specific for SLE
• Anti-Ro/SSA: Associated with photosensitivity, subacute cutaneous lupus, neonatal lupus, congenital heart block
• Anti-La/SSB: Often accompanies anti-Ro
• Anti-U1-RNP: Associated with mixed connective tissue disease features
• Anti-ribosomal P: Associated with neuropsychiatric SLE and lupus hepatitis

Step 4: Additional Serologic Testing

Complement levels 2:

• Low C3 and C4 support active SLE, particularly with renal involvement
• Essential for both diagnosis and monitoring

Anti-C1q antibodies 2:

• Present in 30-60% of SLE patients
• Found in nearly 100% of active lupus nephritis
• High negative predictive value (flare unlikely if absent)

Antiphospholipid antibodies 2:

• Anticardiolipin, anti-β2-glycoprotein I, lupus anticoagulant
• Present in 30-40% of SLE patients
• Increases diagnostic likelihood when clinical suspicion exists

Anti-nucleosome antibodies 2:

• Consider when clinical suspicion is high but anti-dsDNA is negative
• 83% sensitivity, 97% specificity for SLE
• May precede anti-dsDNA positivity in disease evolution

Clinical Assessment Framework

Essential Clinical Manifestations to Document

Constitutional: Fever (without infection), fatigue, weight loss

Mucocutaneous 1, 3:

• Malar (butterfly) rash
• Discoid lesions
• Photosensitivity
• Oral/nasal ulcers
• Non-scarring alopecia

Musculoskeletal 3:

• Non-erosive arthritis (typically symmetric, small joints)
• Arthralgia without synovitis

Renal 2, 3:

• Proteinuria >0.5g/24hr or urine protein/creatinine ratio >0.5
• Active urinary sediment (RBC casts, hematuria, pyuria)
• Biopsy-proven lupus nephritis

Hematologic 3, 4:

• Leukopenia (<4000/mm³)
• Lymphopenia (<1000/mm³)
• Thrombocytopenia (<100,000/mm³)
• Autoimmune hemolytic anemia

Neuropsychiatric 3:

• Seizures (exclude other causes)
• Psychosis (exclude other causes)
• Mononeuritis multiplex
• Cognitive dysfunction

Cardiopulmonary 3:

• Serositis (pleuritis, pericarditis)
• Myocarditis
• Libman-Sacks endocarditis

Application of EULAR/ACR 2019 Classification Criteria

Entry criterion: ANA ≥1:160 on HEp-2 cells (or equivalent positive test) 2

Scoring system 2:

• Weight clinical and immunologic domains
• Score ≥10 points classifies as SLE
• Anti-dsDNA or anti-Sm antibodies carry highest immunologic weight

Key strength: Superior sensitivity and specificity compared to prior ACR and SLICC criteria 2

Critical Pitfalls to Avoid

1. Do not order ANA reflexively without clinical suspicion - leads to false positives in general population 2

2. Do not rely on automated ANA platforms alone - significant discrepancies exist between IIFA and solid-phase assays; IIFA on HEp-2 cells remains gold standard 1, 2

3. Do not stop at negative anti-dsDNA - up to 30% of SLE patients may be anti-dsDNA negative; proceed with anti-ENA panel 2

4. Do not diagnose based on serology alone - requires integration of clinical manifestations with laboratory findings 2

5. Do not miss drug-induced lupus - anti-histone antibodies more common in drug-induced SLE; consider medication history 2

6. Report laboratory methods used - different platforms yield different results; specify IIFA vs solid-phase assay, CLIFT vs Farr assay 1, 2

Special Diagnostic Scenarios

High clinical suspicion with negative ANA 1, 2:

• Order specific antibodies directly: anti-Ro/SSA (for subacute cutaneous lupus, Sjögren's overlap), anti-ribosomal P (for neuropsychiatric SLE), anti-Jo-1 (if myositis features)
• Consider anti-nucleosome testing
• Arrange clinical follow-up every 6 months as antibodies may appear later

Discordant anti-dsDNA results 2:

• Repeat testing in new sample
• If discordance persists, diagnosis depends on clinical characteristics
• Positive CLIFT with negative SPA strongly suggests SLE
• Positive SPA with negative CLIFT requires clinical correlation and follow-up

Pediatric considerations 5:

• Same diagnostic approach applies
• Higher frequency of severe manifestations at presentation
• More aggressive renal and CNS involvement

When to Refer to Rheumatology

Immediate referral 6, 7:

• Positive ANA with compatible clinical features
• Suspected lupus nephritis (proteinuria, active sediment)
• Neuropsychiatric manifestations
• Severe cytopenias
• Multi-organ involvement

Delays in diagnosis increase organ damage and mortality 2 - early rheumatology involvement is essential for optimal outcomes.